Danaher Executive Vice President Sold Shares Worth Over $4M

Danaher's Executive Vice President Matthew McGrew sold 17,385 shares at $235.69 per share, totaling $4.1M. He now directly owns 12,674 shares and indirectly owns 10,293 shares through a 401(k).

Original reporting
Published Nov 10, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Danaher Executive Vice President Sold Shares Worth Over $4M — source image
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

The $4.1M sale by an executive may be interpreted as a bearish cue, but the amount is modest relative to Danaher's market cap.

02

Market read

Provides a fresh data point for traders monitoring insider activity at Danaher.

03

What to watch

No immediate earnings or strategic changes accompany the sale.

Relevance 6/10Novelty 6/10Timing: after-hours filing

Background

Form 4 disclosures provide transparency on insider transactions.

Company-level read

Ticker impact

$DHRBearishHigh confidence
Context

Danaher EVP Matthew McGrew sold 17,385 shares for $4.1M, reducing his direct and indirect holdings.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 filings are primary disclosures; a $4M sale by a senior executive is material for a large‑cap.

Market effects

Minimal impact on the broader industrial conglomerate sector.

Limited to U.S. investors tracking Danaher.

Low; the news is company‑specific.

Counterpoint

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Matthew McGrew

    Executive Vice President of Danaher who sold shares.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.